Antiviral chemotherapy--a frontier for health and learning. by Jackson, G. G.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 55 (1982), 369-374
Antiviral Chemotherapy-
A Frontier for Health and Learning
GEORGE GEE JACKSON, M.D.
Robert WoodKeeton Professor ofMedicine, Chief, Section ofInfectious Diseases,
Department ofMedicine, University ofIllinois, College ofMedicine, Chicago, Illinois
Received May 24, 1982
Antiviral chemotherapy has been too long perceived as being relatively impossible. Such no-
tions adversely affect the acquisition of important specific clinical information, whereas much
new knowledge is available about viral replication and cell biology which enhances the pros-
pects for effective chemotherapy. Some immediate goals can be recognized that will further
determine the ability to influence viral infections and properly interpret the drug effects. In re-
cent controlled observations there is reason for expectant optimism, but the demonstration of
antiviral chemotherapy is both disease- and host-dependent, with important nonpharmacologic
aspects. Rapid specific and sensitive diagnostic tests are of paramount importance; that they
can be devised is a generally accepted conclusion among virologists. Problems in the scientific
evaluation of antiviral chemotherapy in man have led to the recommendations of compounds
that have no proved effect; amantadine, Ara A, and interferon, however, have been shown to
be efficacious. Acyclovir and bromvinyldeoxyuridine have demonstrated virus-directed
chemotherapy with impressive specificity. The frontier of antiviral chemotherapy holds great
promise for additional learning and improved health through the implementation of develop-
ing knowledge.
A PERSPECTIVE
Within broad segments of the medical profession and lay persons, there are some
engrained perceptions and preconceptions about viral diseases and antiviral chemo-
therapy. Often the notions tend to be negative, uncritical, inaccurate, or at best
pragmatic. They exert a stultifying influence on the challenge ofunderstanding viral
infections and their control, on the desire for the specific diagnosis of viral diseases
to define their clinical spectrum and epidemiology, and on developing more com-
plete knowledge about the vital biology of the interactions among viruses, cells, the
immunologic system, and the regulatory mechanisms of each of them. In other
respects, the common views are realistic or at least defensible in the context of the
relatively benign nature ofmost viral infections and the historical successes (or more
often lack of success) from the clinical application of antiviral chemotherapy. But
the belief that successful drug treatment of viral infections is impossible is wrong. It
ignores important needs and the availability of knowledge about basic cellular
biology (and even engineering) that could be applied to viral infections and the ef-
fects of drugs in altering them. Thus antiviral chemotherapy is an exciting frontier
with opportunities for making major contributions to improved health from the
control of acute, persistent, and latent viral infections that are highly prevalent
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among people in both the developed and underdeveloped countries of the world.
Like other frontiers it has a relative poverty of funds, some deficiencies in skills, has
suffered setbacks from failures, but has promise for the future through developing
the biologic research and clinical experience that is required. The axiom, "It is not so
important where we are, but the direction we are going," aptly applies to the field of
antiviral chemotherapy, and the direction is impressively forward.
SOME IMMEDIATE GOALS
Among the things that are necessary in order to further the progress in antiviral
chemotherapy, we must:
1. disavow the engrained belief that antiviral chemotherapy is unlikely
because of the intracellular location of viral infections and the similarity of
virus replication to cellular metabolism;
2. determine the amount of disease that is reversible by antiviral contain-
ment of viral replication and establish the limits of the incisive period during
which antiviral chemotherapy can be useful;
3. develop and apply easy methods for rapid, specific diagnosis ofviral in-
fection;
4. improve general awareness of knowledge about specific drugs with
demonstrable antiviral activity in man, extend the understanding of the basis
(mechanisms) oftheir action, and devise new modes to solve the problems of
how to make them rapidly available and deliver them safely and effectively;
5. establish practical goals for the clinical application of antiviral drugs to
achieve effective prophylaxis against infection and illness (as an adjunct to
vaccines) and fortherapy that will be understandable and useful to physicians
and acceptable to consumers;
6. research additional needs for antiviral chemotherapy, especially a
means for control of in vivo reservoirs of latent viruses, quenching virus (and
incomplete virus) production in chronic, persistent infections, and preventing
viral transformation of cells, tumor formation, or cancer;
7. learn the optimum collaboration between drugs and the host defense
systems to remedy specific host deficiencies and to augment the beneficial
and depress the pathologic host immunologic responses initiated by viral in-
fections.
A BASIS FOR EXPECTANT OPTIMISM AND NEED
In recent years controlled trials have provided measurable clinical benefit from
antiviral chemotherapy [1,2,3,4,5,6]. Already chemoprophylaxis or treatment is
definitively established for ulcerative herpetic keratitis, herpes simplex encephalitis
(when biopsy-proven of recent onset), varicella zoster (among patients with
leukemia and/or those who are immunosuppressed), and influenza A. Investiga-
tional studies are in progress with promise in the treatment ofherpes labialis, genital
herpes, varicella zoster in the nonimmunocompromised person, chronic active
hepatitis B virus infection, influenza B, and other viral pneumonias. Also there is
perhaps a broader opportunity for effective application of antiviral chemotherapy
owing to the emergence of certain viral infections because of an aging population,
iatrogenic immunosuppression, more intensive care of patients with cancer, in-
creased sexual activity at an earlier age with a more permissive social fabric at all
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ages, intrauterine and postnatal diagnosis of vertical and neonatal transmission of
viral infections, recognition of the high prevalence of some chronic, persistent, and
slow virus infections, and the continuing frequent affliction of the general popula-
tion with acute viral infections of the respiratory, enteric, and central nervous
systems. Varicella zoster is among the most rapidly increasing diseases ofthe elderly;
genital herpes is estimated to occur in 20 percent of young, sexually active persons,
and HSV-2 with its greater propensity for latent infection of sacral ganglia and
recurrences now accounts for more than 90 percent of these infections [7,8]. Active
infection with hepatitis B virus can be found in as many as 2 percent of certain
hospital populations in developed countries and 10 percent of the population of
some other countries [9]. Cytomegalovirus affects about 0.5 percent of live births
and is considered to be among the leading causes of deafness; rubella persists as a
cause of infant abnormalities. Vaccines are available or being developed to prevent
some of these diseases and, when effective, should be advocated for broad use.
However, many biologic and social conditions demand chemotherapy as an adjunc-
tive or necessary measure. While research is increasing the number ofknown specific
kinds of viral infections, established and new technology is improving the accuracy
of diagnosis of their occurrence. Together these efforts are reducing the unknown
segment of viral diseases and providing the knowledge required for effective anti-
viral chemotherapy. Concomitantly, antiviral drugs with potent antiviral activity,
a high degree of virus host selectivity, and improved pharmacologic properties are
being developed. In these several diverse but related areas, the frontier for health im-
provement through antiviral chemotherapy is being mapped and readied for settle-
ment.
DISEASE-DEPENDENT DEMONSTRATION
OF ANTIVIRAL CHEMOTHERAPY
The evaluation of antiviral drugs has required the reemphasis of several disease-
related events that confound and/or limit the demonstration of benefit from anti-
viral chemotherapy. These include the presence of an early signal of infection, ob-
jective signs that can be quantitatively measured, and a general predictability of the
clinical course that permits differentiation of untreated persons with the disease.
These are not unique to antiviral chemotherapy, but the nature ofviral infections ex-
aggerates them because of the often silent nature of the infection well in advance of
the clinical syndrome. In antiviral chemotherapy this disease dependence may be a
problem with greater need for attention than the discovery of new antiviral drugs.
Considerable improvement in astute clinical observations and confirmatory tests
must be realized to counter the dependence on the insidious production ofsymptoms
in order to permit the initiation of antiviral chemotherapy at a time when there is
still gain to be realized from the inhibition of virus replication. Such an opportunity
always exists, but the time-critical period for the effective and beneficial application
of antiviral chemotherapy in acute viral infections may be, relatively, exceedingly
brief. Thus the earliest successes and best demonstration of antiviral chemotherapy
have come in those diseases where the features noted above can be met. Ifthe disease
is severe, as with herpes encephalitis or lassa fever (in primates) with death or
disability as an end point that has not been predetermined by the stage of disease, a
therapeutic effect of antiviral chemotherapy can be demonstrated [1]. Some other
objective sign that can be observed and measured, such as a dendritic ulcer, serves
the same purpose. But if the disease is mild and brief, such as herpes labialis, genital
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herpes in antibody-positive persons, herpes zoster in a nonimmunocompromised
host, or Influenza A (H,N,) in healthy young students, the race to hasten the cure by
antiviral treatment before it is accomplished by natural host defenses requires more
subtle measures such as the duration of fever, time to healing, altered function tests,
or the persistence of infectious virus [10,11]. If the therapeutic effect is subliminal,
its presence or absence may be clinically moot, but nevertheless defensible to affect
and prevent the most severe variants of the disease. Improvement of host responses
increases the scope for a demonstrable drug effect. Thus the predictability of the
course as affected by the host is a part of the disease-dependent demonstration ofef-
fective antiviral chemotherapy [12].
Because timing is critical for effective antiviral treatment, prophylactic use of an
antiviral drug offers the greatest, and sometimes, depending on the action of the
drug, the only easily demonstrable effect. Prophylactic chemotherapy requires that
the drug be readily available, and because protection lasts only as long as the drug is
taken, it needs to be safe for long periods ofadministration; also, the likelihood ofa
significant exposure to infection must be great enough to produce a clinical differ-
ence among drug-treated and untreated persons, and in practice be cost-effective.
These disease-dependent features that impinge on effective antiviral chemo-
therapy pose major nonpharmacologic sociomedical challenges. Effective antiviral
chemotherapy most likely will require a willingness to modify standard post-illness
therapeutic prescription practices, broader use ofepidemiologic clues to identify the
earliest signs ofinfection, new uses ofmodern communication media for lay instruc-
tion, and, in some cases, the establishment of new therapeutic goals such as de-
creased transmission of virus and prophylactic treatment of contacts.
SPECIFICITY AND SENSITIVITY IN THE
RAPID DIAGNOSIS OF VIRAL INFECTIONS
The cliche, "It's a virus," is stone-age medicine in the context of modern virology.
Uncritical satisfaction with that level of clinical diagnosis has lasted so long for
several reasons, partly because the technology for rapid, sensitive, and specific diag-
nosis of viral diseases isjust beginning to be mobilized for clinical applicability. The
intimate nature of the virus-host cell relation increases the likelihood of need for
biochemical and biologic specificity in the antiviral effects of drugs. The need for
such specificity in conjunction with the time-critical nature of antiviral chemother-
apy makes it apparent that rapid specific diagnosis is of paramount importance in
the future development and success of antiviral chemotherapy and that the
diagnostic tests must be sensitive enough for the identification of a small amount of
virus or viral product at an early stage of infection. That the needed diagnostic tests
for rapid and specific identification of viral diseases at a high level of sensitivity
could be developed is now a recognized conclusion of most virologists. The impetus
to do so is intertwined with the improved outlook for antiviral chemotherapy.
Although virus isolation and identification offer the standard proof of a cause-and-
effect relation with the disease, the time required makes the outcome of only con-
firmatory help in most applications of antiviral chemotherapy. Morphologic
recognition of the virus by immunoelectronmicroscopy can be faster than virus
recovery and applicable to some viruses for which recovery systems are difficult.
Other tests for the physicochemical, immunologic, or radiologic detection of viral
antigens, a viral gene, or gene product by counter immunoelectrophoresis, im-
munofluorescence, enzyme-linked immunospecific assay, radiolabeled reagents, and
fluorescein labeled substrates can reduce the time required for the availability of
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results to a few hours and increase the sensitivity of detection to as high as one part
in a 10-12 dilution in body fluids or secretions while retaining exquisite specificity
[13]. The further development and application ofthese tests to identify and differen-
tiate specific viral diseases rapidly at an early stage of infection, when therapeutic
and control measures will be most beneficial, is another frontier which is already
well defined, and its fulfillment is but a matter of education, interest, and time with
the development of antiviral drugs having promise in the clinical improvement of
specific viral infections.
WELL-TESTED ANTIVIRAL AGENTS OF IMPORTANCE AND
NO IMPORTANCE IN HUMAN DISEASE-PRESENT AND FUTURE
Owing to the foregoing difficulties, the differentiation between testimonial and
scientific evidence in determining the efficacy of antiviralchemotherapy for systemic
viral diseases has sometimes posed a problem. Vitamin C, levamisole, 2-deoxy D
glucose, cytosine arabinoside, topical ether, aspirin, and lysine are among recently
recommended remedies that have been quite well tested in humans but for which lit-
tle or no scientific data support the claim of efficacy. Other modalities of treatment
such as photosynthetic inactivation of viruses mediated by aromatic dyes, if effec-
tive in decreasing infectious virus, leave functional expression of viral genes that is
undesirable. Several compounds that are effective have been too toxic or have phar-
macologic properties that are unmanageable for clinical use.
On the other hand, well-controlled investigations and confirmatory experience
have established that a significant prophylactic or therapeutic benefit can be derived
from amantadine, ara A, and interferon under specific conditions of application
[3,4,5,6,14]. Consensus about the recommendations for their use is beginning to
evolve [15]. Each probes different mechanisms of selective chemotherapeutic anti-
viral actions, and thus provides encouragement for exploring the multiplicity of po-
tential opportunities of developing antiviral drugs [16]. Added to the modest suc-
cesses that have been obtained is the promise of acyclovir, bromvinyldeoxyuridine,
and other substituted nucleosides with a selectivity that is activated and directed by
viral products and amplified in the specificity of inhibitory action against viral as
compared to mammalian polymerases, and that have the potential for oral use
[17,18,19,20]. Other compounds with other mechanisms ensure that additional in-
vestigational new drugs will appear. With them, antiviral chemotherapy should pro-
gressively move into the realm of clinical practice with abandonment of the confin-
ing views that have been so prevalent. If this is so, a rewarding development of this
frontier can be anticipated, with improved health and further learning through the
implementation of our improving knowledge of viruses, viral infections, cellular
regulation, rapid specific diagnosis, and the ability to evaluate selectively tailored
antiviral drugs.
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